Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 65 citing articles:

Efficacy and safety of COVID-19 vaccines
Carolina Graña, Lina Ghosn, Theodoros Evrenoglou, et al.
Cochrane library (2022) Vol. 2023, Iss. 3
Open Access | Times Cited: 254
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
EClinicalMedicine (2022) Vol. 51, pp. 101569-101569
Open Access | Times Cited: 83
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Vincent Pavot, Catherine Berry, Michael Kishko, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 41
A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults
Kun Xu, Zihan Wang, Maorong Qin, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 33
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Angela R. Branche, Nadine Rouphael, David Diemert, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2334-2346
Open Access | Times Cited: 33
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
Júlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
The Lancet Regional Health - Europe (2023) Vol. 28, pp. 100613-100613
Open Access | Times Cited: 24
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
pH-Sensitive and Biodegradable Mn3(PO4)2·3H2O Nanoparticles as an Adjuvant of Protein-Based Bivalent COVID-19 Vaccine to Induce Potent and Broad-Spectrum Immunity
Shihao Zhou, Ru-Yan Zhang, Zi-Wei You, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 7, pp. 8914-8926
Closed Access | Times Cited: 16
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
Guy de Bruyn, Joyce Wang, Annie Purvis, et al.
EClinicalMedicine (2023) Vol. 62, pp. 102109-102109
Open Access | Times Cited: 16
The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2
Yuan Hu, Lili Liu, Shenghua Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 5, pp. 5175-5192
Open Access | Times Cited: 6
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth
Katrina M. Pollock, Hannah M. Cheeseman, Leon R. McFarlane, et al.
EBioMedicine (2025) Vol. 112, pp. 105544-105544
Open Access
A synthetic cyclic peptide for promoting antigen presentation and immune activation
Jiahui Zhang, Harrison Y. R. Madge, Asmaa Mahmoud, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses
Angela R. Branche, Nadine Rouphael, David Diemert, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 26
Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning
Wenhao O. Ouyang, Timothy J.C. Tan, Ruipeng Lei, et al.
Science Advances (2022) Vol. 8, Iss. 47
Open Access | Times Cited: 26
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, et al.
Med (2022) Vol. 3, Iss. 11, pp. 760-773.e5
Open Access | Times Cited: 25
Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant
Waranyoo Phoolcharoen, Balamurugan Shanmugaraj, Narach Khorattanakulchai, et al.
Vaccine (2023) Vol. 41, Iss. 17, pp. 2781-2792
Open Access | Times Cited: 13
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates
Vincent Pavot, Catherine Berry, Michael Kishko, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial
Angela R. Branche, Nadine Rouphael, Cecilia Losada, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 4, pp. 560-564
Open Access | Times Cited: 12
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Gustavo H. Dayan, Nadine Rouphael, Stephen R. Walsh, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 11, pp. 975-990
Open Access | Times Cited: 12
Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice
Muhammad S. Khan, Eun Sun Kim, Shaohua Huang, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 314-314
Open Access | Times Cited: 11
Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18–70 Years; A Randomized, Double-Blind Clinical Trial
Arash Mohazzab, Mohammad Hossein Fallah Mehrabadi, Ali Es‐haghi, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 112, Iss. 12, pp. 3012-3021
Closed Access | Times Cited: 10
COVID-19 Vaccines: Where Do We Stand at the End of 2023?
Kenneth Lundström
(2024)
Open Access | Times Cited: 3
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2
Eduardo M. Bruch, Shaolong Zhu, Lisa Szymkowicz, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top